BioSpace News Archive

Acutus Medical, Inc., an arrhythmia management company focused on improving the way cardiac arrhythmias are diagnosed and treated, announced that David Roman has been appointed President and Chief Executive Officer, and member of the Board of Directors, effective immediately.

Quest Diagnostics Incorporated, the world’s leading provider of diagnostic information services, announced financial results for the second quarter ended June 30, 2022.

Today, Vivre 100 Fibromes (Living Without Fibroids) officially declared July 21st as the first Fibroids Awareness Day in Canada.

Skye Bioscience, Inc. (OTCQB: SKYE) (“Skye” or the “Company”), a pharmaceutical company developing a proprietary, synthetic cannabinoid derivative to treat glaucoma, has selected NextPharma as its contract manufacturing organization (“CMO”) for its Phase 2 clinical trial material.

Shanghai Junshi Biosciences Co., Ltd announced today that toripalimab, a PD-1 inhibitor independently developed by Junshi Biosciences is designated as an orphan medicinal product by the European Commission.

iSpecimen Inc. today announced that it will report its financial results for the second quarter ended June 30, 2022, before the markets open on Thursday, August 4, 2022.

Organon (NYSE: OGN), a global women’s healthcare company will release its second quarter 2022 financial results on August 4, 2022, prior to the company’s webcast and conference call scheduled for 8:30 a.m. EDT.

ReWalk Robotics Ltd. (Nasdaq: RWLK) (the “Company” or “ReWalk”), a leading manufacturer of robotic medical technology for people with lower extremity disabilities, today announced that it has received Israeli court approval to repurchase up to $8 million of its Ordinary Shares, par value NIS 0.25 per share.

PTC Therapeutics, Inc. (NASDAQ: PTCT) today announced that the company will host a webcast conference call to report its second quarter 2022 financial results and provide an update on the company’s business and outlook on Thursday, Aug. 4 , at 4:30 p.m. ET .

The University of Texas MD Anderson Cancer Center and Obsidian Therapeutics, Inc. today announced Food and Drug Administration (FDA) clearance of an Investigational New Drug (IND) application for an MD Anderson-sponsored Phase I clinical study of OBX-115, Obsidian’s lead engineered tumor infiltrating lymphocyte (TIL) therapy candidate.